Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Ye Guo, Jin Li, Zhixiang Zhuang et al.|Journal of Clinical Oncology|2023Cited by 11